logo

For the Inventor, By the Inventor

Boston, MA, United States of America

Alexion Pharmaceuticals, Inc.


USPTO Granted Patents = 196



Trademarks = 23

Forward Citations = 1,674

Loading Chart...
Loading Chart...

233 inventors (with patents filed for the assignee):

goldMedal Russell P Rother (36 out of 38 patents)

silverMedal Katherine S Bowdish (27 out of 27 patents)

bronzeMedal Douglas L Sheridan (24 out of 24 patents)

4.  Paul P Tamburini (21 out of 28 patents)

5.  Yi Wang (20 out of 21 patents)

6.  Stephen P Squinto (12 out of 16 patents)

7.  John R McWhirter (12 out of 75 patents)

8.  Anthony Quinn (11 out of 14 patents)

9.  Anke Kretz-Rommel (11 out of 14 patents)

10.  Scott A Rollins (11 out of 18 patents)

11.  Leonard Bell (10 out of 14 patents)

12.  Bruce A Andrien, Jr (10 out of 27 patents)

13.  Shana Frederickson (10 out of 10 patents)

14.  Yuchun Zhang (9 out of 9 patents)

15.  Toshiaki Maruyama (9 out of 10 patents)


Core Competencies:
Anti-C5 Antibodies
Alkaline Phosphatase Polypeptides
Cerdulatinib
Factor Xa Antidotes
Atypical Hemolytic Uremic Syndrome
Lysosomal Storage Disease Enzymes
Humanized Antibodies
Protein Kinase Inhibitors
B-Cell Malignancies
Neurofibromatosis Treatment
Paroxysmal Nocturnal Hemoglobinuria
Recombinant Proteins

196 patents:

1. 12460012 - Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients (2025-11-04),
2. 12459992 - Methods for treatment of refractory generalized myasthenia gravis (2025-11-04),
3. 12433938 - Alkaline phosphatase polypeptides and methods of use thereof (2025-10-07),
4. 12428484 - Anti-ALK2 antibodies and uses thereof (2025-09-30),
5. 12404320 - Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients (2025-09-02),
6. 12398387 - Compositions and methods for preparing factor Xa and derivatives (2025-08-26),
7. 12350269 - Cerdulatinib for the treatment of b-cell malignancies (2025-07-08),
8. 12312394 - Methods of producing anti-C5 antibodies (2025-05-27),
9. 12268733 - Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase (2025-04-08),
10. 12240893 - Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) (2025-03-04),
11. 12233088 - Bis-choline tetrathiomolybdate for treating Wilson Disease (2025-02-25),
12. 12221473 - Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof (2025-02-11),
13. 12195774 - Antidotes to factor XA inhibitors (2025-01-14),
14. 12150942 - Cerdulatinib for treating myeloma (2024-11-26),
15. 12139533 - Liquid formulations of anti-CD200 antibodies (2024-11-12),
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing life-transforming therapies for patients with severe and rare diseases. With a mission to transform the lives of people affected by rare diseases, Alexion specializes in rare and ultra-rare disorders, including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis (gMG). Through innovative research and development, Alexion is committed to delivering innovative therapies that address the underlying cause of these diseases and bring hope to patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
196 Patents

#18 in Boston, MA

#120 in Massachusetts

#2,031 in US

#4,186 in the World

...
Boston, MA, United States of America

Alexion Pharmaceuticals, Inc.

Forward Citations = 1,674

233 inventors:

goldMedal Russell P Rother (36 out of 38 patents)

silverMedal Katherine S Bowdish (27 out of 27 patents)

bronzeMedal Douglas L Sheridan (24 out of 24 patents)

4.  Paul P Tamburini (21 out of 28 patents)

5.  Yi Wang (20 out of 21 patents)

Please report any incorrect information to support@idiyas.com
Loading…